Kevin Helash - 12 Jul 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 12 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jul 2022, 21:33:50 UTC
Prior SEC filing: 18 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Linda V. Moore, as attorney in fact

Key filing fact

Kevin Helash filed Form 4 for MARRONE BIO INNOVATIONS INC on 14 Jul 2022.

Key facts

This page summarizes Kevin Helash's Form 4 filing for MARRONE BIO INNOVATIONS INC.
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Jul 2022, 21:33.

Change

Previous filing in this sequence was filed on 18 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MBII transaction

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -241,568
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Jul 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBII transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -417,273
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 417,273
Exercise price: $0.6321
Footnotes: F2

MBII transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -2,450,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,450,000
Exercise price: $1.16
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Kevin Helash is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Certain unvested restricted stock units became vested and all vested restricted stock units were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement") in exchange for 14,482 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 6,776 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).

Footnote F2

This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 237,611 shares and replaced with an option to purchase 15,810 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 9,042 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.

Footnote F3

This option, which provided (1) with respect to 225,000 options, for vesting of 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 3, 2020, with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months; (2) with respect to 2,000,000 options, for vesting if/when performance milestone is attained; and (3) with respect to 225,000 options, for vesting over a period of four years as measured from the vesting commencement date of August 4, 2020, on a pro-rata basis equally each month, was assumed by BIOX in the Merger and replaced with an option to purchase 215,600 Ordinary Shares of BIOX for $13.18 per share.